Mycosis Fungoides
Pipeline by Development Stage
Drug Modality Breakdown
Competitive Landscape
11 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (12)
Total enrollment: 1,227 patients across 12 trials
Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides
Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.
The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients
Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides
Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma
Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.